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Background: Lymphatic filariasis is targeted for elimination in India through mass drug administration (MDA) with
diethylcarbamazine (DEC) combined with albendazole (ABZ). For the strategy to be effective, >65% of those living
in endemic areas must be covered by and compliant to MDA. Post the MDA 2011 campaign in the endemic district
of Odisha, we conducted a survey to assess: (i) the filariasis knowledge in the community, (ii) the coverage and
compliance of MDA from the community perspective, and (iii) factors affecting compliance, as well as the
operational issues involved in carrying out MDA activities from the drug distributor’s perspective.
Methods: A sample of 691 participants – both male and female, aged two years or above – were selected through
multistage stratified sampling and interviewed using a semi-structured questionnaire. Additionally, drug distributors
and the medical officers in charge of the MDA were also interviewed to understand some of the operational issues
encountered during MDA.
Results: Ninety-nine percent of the study participants received DEC and ABZ tablets during MDA, of which only
just above a quarter actually consumed the drugs. The cause of non-compliance was mostly due to fear of side
effects, lack of awareness of the benefits of MDA, and non-attendance of health staff in the villages. Lack of adequate
training of drug distributors and poor health communication activities before the MDA campaign commenced and the
absence of follow-up by health workers following MDA were a few of the operational difficulties encountered during
the MDA campaign.
Conclusion: Currently MDA is restricted to the distribution of drugs only and the key issues of implementation in
compliance, health education, managing side effects, and logistics are not given enough attention. It is therefore
essential to address the issues linked to low compliance to make the program more efficient and achieve the goal of
filariasis elimination.
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Lymphatic filariasis (LF) or elephantiasis is one of the
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unless otherwise stated.the fourth most common cause of disability worldwide
[2]. The infection is endemic in more than 80 countries,
with more than 1.3 billion people at risk and 120 million
already infected globally [1]. Two-thirds of the endemic
population resides in South-East Asia and one-third lives
in India [3]. Considering the human suffering, social
stigma and costs associated with LF morbidity, and in
response to the specific resolution by the World Health
Assembly, the Global Program to Eliminate Lymphatic
Filariasis (GPELF) was launched by the World Health
Organization (WHO) in 2000 with the goal of eliminat-
ing LF as a public health problem by the year 2020 [4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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eliminate LF by 2015 [5]. In order to achieve this goal, a
“two-pillars” strategy of interrupting transmission through
mass drug administration (MDA) with diethylcarbamazine
(DEC) and providing care for those with the disease was
adopted [6].
India’s filarial control program has scaled up MDA
over the past several years and recently added albenda-
zole (ABZ) to the treatment of the 590 million Indians
living at risk of infection [7]. The principle behind MDA
is that a single dose of DEC administered annually con-
tinued for four to six years will interrupt the transmis-
sion of filariasis [8]. Micro-simulation models showing
the effect of MDA on LF elimination demonstrate that
the number of MDA rounds necessary to achieve elimin-
ation depends, to a large extent, on coverage, drug
efficacy, and the endemicity level [9] Countries such as
India have additional challenges due to the many diverse
geographical areas with high endemicities of filariasis,
the populations of which will require more rounds of
MDA. Despite this, the program has been successful in
distributing a sufficient number of tablets to the high-
risk population. However, ensuring adherence and com-
pliance to the regimen is still a problem in many parts
of country [10,11].
In India, the coverage levels varied from 55% to 90%
[12]. When a proportion of the population fails to com-
ply with MDA, a potential reservoir for the parasite is
left untreated, opening the door to recrudescence of the
microfilaraemia (mf) and thus reducing the probability
of the program’s success [13]. It is estimated that in
order to interrupt transmission, MDA compliance must
exceed 65–75%, with five to six rounds of treatment [9],
however, compliance is relatively low in the majority of
the endemic areas [10,14,15]. Odisha has reported an mf
rate of 0.43 in 2011 compared to 2.57 in 2004 [16].
However, coastal districts are more endemic for the
disease, particularly the district Puri. Considering the
fact that many of Odisha’s non-coastal districts were
non-endemic for filarial, this reported mf rate could be
misleading.
In support of this, various research has reported low
compliance rates in endemic districts [17-19]. Studies
have shown that various factors responsible for compli-
ance varied according to the geographical area and
health system function [20,21]. Many studies have been
done to find out the reasons from the community per-
spective, but very few made attempts to understand the
operational issues from the distributor’s perspective. The
roles of the drug distributors and other health workers
cannot be ignored in order to achieve success in MDA
coverage and compliance. Keeping this in mind, this
cross-sectional survey was carried out in the Puri district
of Odisha state in India. The recent round of MDAactivity prior to the study was carried out in March
2011. Intensive behaviour change communication (BCC)
aactivities were carried out to make the community
aware of the facts pertaining to LF and cooperate in the
consumption of the drug. We conducted the study from
April 1 to June 30, 2011, with the objectives to assess
the knowledge of filariasis, the coverage and compliance
of MDA during this period, and to explore the factors
affecting compliance and the operational issues involved
in carrying out MDA activities from the perspective of
the medical officers and drug distributors.
Methods
Study area
The district Puri situated on the coast of the Bay of
Bengal is one of the highly endemic districts for LF and
was considered to have low coverage of MDA since
2002. Presently, around 1.5 million people are at risk of
filarial infection in the district. The district is divided ad-
ministratively into 11 blocks, out of which four are pre-
dominantly urban and seven are rural.
Study design, setting, and participants
To achieve the framed objectives, three different cat-
egories of study participants were selected. For the as-
sessment of coverage and compliance, a representative
sample of individuals aged two years or above was se-
lected. Any individual severely ill or pregnant was excluded.
Furthermore, to have an idea about the operational issues or
problems during the drug distribution, the medical officer in
charge of the community health center (situated in the
selected blocks and responsible for all program activities)
who was responsible for the MDA and one health worker
from each sampled area were also interviewed.
Sample size and sampling technique
The sample size was calculated based on the previous
reported compliance of MDA in the study district [12].
Taking into consideration the MDA compliance in the
study district to be 72%, with an absolute precision of
5% and at a 5% level of significance with a design effect
of two, the sample size was calculated to be 620. Assum-
ing a non-response rate of 10%, the final sample size was
rounded up to 691 calculated using OpenEpi, version
2.3.1 [22]. An equal proportion of participants was
selected from each block and included in the study
through multistage sampling. Initially, a list of all the vil-
lages in each block, as well as the wards in each urban
administrative unit, was prepared and one village/ward
was selected randomly from each block for the selection
of the study respondents. In total, seven villages and four
urban wards were selected representing each administra-
tive block.
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extended program for immunization EPI recommenda-
tion [23], and thereafter the fifth nearest household was
selected to give a widespread coverage and adequate rep-
resentation [24]. All the eligible members of the house-
hold were interviewed about coverage and compliance.
If someone was absent during the day of the interview,
this person’s information was not collected. The children
below 10 years of age were not assessed for knowledge
of LF. For those children who were not sure about the
receipt and consumption of drugs, the information was
ascertained from their mothers or any available adult
family member who was aware of their consumption
status. If one village was not covered in one day then a
second visit was made to complete the interviews. In
total, 11 medical officers and 11 drug distributors/health
workers were included in the study.Data collection and study variables
Data was collected with the help of an interviewer-
administered questionnaire containing both open- and
closed-ended questions. All interviews were conducted
by one of the authors, AKS, who is a trained medical
graduate and well versed in the local health system, as
well as the local communities. Three different sets of
questionnaires were used, one for the individual respon-
dents (eligible representative sample), one for the drug
distributors, and one for the medical officers. Items and
possible options for the questions were decided upon
based on the personal experiences of the researchers,
from available published literature, and from a pilot
qualitative study done prior to this study.
The assessment of the coverage and compliance was
for the round of MDA conducted in March 2011. Since
the data collection for the study was done during April
and May 2011, which was one month after the MDA
round, the chances of experiencing recall bias was as-
sumed to be less. For all practical purposes, coverage
and compliance were defined as follows:
Coverage was defined as the percentage of eligible
individuals who received the drugs DEC and ABZ
distributed during the MDA in March 2011.
Compliance was defined as the percentage of
individuals who self-reported that they consumed the
drugs, among those who received the drugs.
The socio-demographic variables studied were age, sex,
education, occupation, and place of residence. In relation
to the compliance, data was obtained on the number of
tablets taken, whether the drug was taken under direct ob-
servation of the drug administrator, any side effects expe-
rienced, and the reasons for non-compliance.The respondents’ basic knowledge of filariasis, particu-
larly its causative agent, signs and symptoms, treatment
options, individual perception about susceptibility to fil-
arial infection and awareness about MDA, were also ex-
plored. Similarly, the questionnaire for the health workers/
drug distributors was designed to elicit how they procured
and distributed drug, what they advised patients, and the
problems they faced during drug distribution. The ques-
tionnaire for the medical officers attempted to explore the
operational difficulties during the MDA program.
Data entry and analysis
The data from the household survey form was entered
into MS Excel spreadsheet and analyzed using SPSS ver-
sion 15.0.
The coverage and compliance were calculated in per-
centages and their population estimates were expressed
in terms of Fleiss quadratic 95% confidence interval (CI)
using Epi Info 6. Other details of compliance and non-
compliance were also expressed as percentages. The chi-
square test was done to assess the significance of the
socio-demographic and other variables related to com-
pliance. The qualitative data (obtained using an open-
ended questionnaire) were analyzed using the “thematic
framework” approach. While synthesizing both the quali-
tative and quantitative data, various themes that influ-
enced coverage and compliance of MDA were identified
and categorized. These included health system/policy,
and community- and drug-related issues. Ethical permis-
sion for the study was obtained from the Institutional
Ethical Committee of the Indian Institute of Public
Health, Bhubaneswar, prior to the study. Written and
verbal consent was obtained from all study participants
before they were included in the study.
Results
Background characteristics
Out of 691 study participants, males and females were
nearly equally distributed. About 59% (95% CI: 54.6%–
62.0%) of the participants were in the age group of 16 to
45 years. The literacy rate among males was higher than
among the females. Individuals from rural areas com-
prised 68.7% of the sample (see Table 1).
Knowledge about filariasis
The study participants demonstrated a good knowledge
of filariasis, as well as of MDA. Nearly 84% (95% CI:
80.7%–86.3%) considered themselves to be at risk of
getting disease and 88% (95% CI: 85.2%–90.1%) cited
mosquito bites as the mode of transmission (see Table 2).
A similar response was obtained when participants iden-
tified the symptoms and treatment for filariasis. We
could not find any association between knowledge and
drug consumption during the MDA program.
Table 1 Socio-demographic characteristics of the study participants
Variables Categories Male (N = 334) % (95% CI) Female (N = 357) % (95% CI) Total (N = 691) % (95% CI)
Age group 3–10 5.38(3.32–8.22) 8.75(6.13–12.05) 7.09(5.35–9.19)
11–15 6.28(4.03–9.29) 15.53(12.0–19.6) 11(8.8–13.5)
16–45 59(53.6–64.1) 58.2(53–63.2) 58.3(54.6–62.0)
>45 29.3(24.6–34.4) 18.3(14.6–22.6) 23.6(20.5–26.9)
Education Illiterate 3.9(2.18–6.4) 6.7(4.5–9.7) 5.3(3.8–7.22)
3–7 years 7.2(4.7–10.3) 27.4(22.9–32.2) 17.5(14.8–20.5)
7–10 years 17.3(15.6–21.7) 22.3(18.2–26.8) 19.8(17.0–23.0)
>10 Years 71.5(66.5–76.2) 44.35(39.2–49.5) 57.3(53.6–61.0)
Area Urban 57.9(51.2–64.3) 41.12(35.6–48.8) 31.3(27.9–34.7)
Rural 50.5(46.0–55.0) 49.4(45.0–54.0) 68.7(65.2–72.1)
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Nearly 99% of the studied individuals in both rural and
urban areas received DEC and ABZ during the MDA
campaign. However, less than a third (28% in the rural
areas and 31% in the urban areas) had consumed the
distributed drugs. There was a significant heterogeneity
(p < 0.001) in the consumption pattern among males and
females with a higher proportion of males consuming
the drugs than females, and also across the educational
status and age group (see Figure 1). No difference was
observed in the consumption pattern among the resi-
dents in rural and urban areas (p = 0.432). The various
reasons expressed by the study participants for non-
consumption are depicted in Figure 2. Out of all of them,
the fear of side effects (77%) was the major cause for non-Table 2 Knowledge of filariasis in the community
Variables Responses
What is filariasis? Elephantiasis
Lymphedema and elephan
Do not know
Mode of transmission for filariasis? Mosquito bite
Hereditary/contagious
Do not know
Most common symptoms Swelling of limbs
Fever and swelling
Do not know
Treatment Medicine
Not curable
Do not know
Knowledge regarding the distribution of filarial
tablets for prevention
Yes
No
Do you consider yourself to be at risk? Yes
No
Do not knowconsumption. The reasons for non-consumption were
probed further and the major responses are depicted in
Figure 3.
Problems faced by the health staff
The discussions with the health workers/drug distribu-
tors highlighted some operational issues, including non-
availability of medicine for side effects and difficulties
in distributing the medicine to everyone in one day,
which pose obstacles in carrying out the MDA activ-
ities. Non-operationalization of behavior change commu-
nication activities before drug distribution, no follow-up
of health workers/drug distributors to ascertain drug in-
take, inadequate training of drug distributors, delay in re-
ceiving funding for MDA activities, and supervisors notMale (N = 334) %
(95% CI)
Female (N = 357) %
(95% CI)
Total (N = 691) %
(95% CI)
61.6(65.4–74.8) 70.3(65.4–74.8) 67.8(64.3–71.3)
tiasis 32.5(27.7–37.5) 29.1(24.6–34.0) 31.7(28.3–35.2)
0.3(0.01–1.4) 0.56(0.1–1.70) 0.43(0.11–1.17)
90.4(86.9–93.2) 85.4(81.5–88.8) 87.8(85.2–90.1)
8.7(6.0–12.0) 13.1(9.9–16.5) 11(8.8–13.5)
0.9(0.22–2.42) 1.4(0.5–3.07) 1.15(0.54–2.2)
60.4(55.2–65.7) 34.0(29.1–39.0) 46.7(43.0–50.5)
38.6(33.5–44.0) 65.2(60.2–70.0) 52.4(48.6–56.1)
0.9(0.22–2.42) 1.12(0.35–2.68) 1.0(0.44–2.0)
90.1(86.5–93.0) 85.0(80.5–88.0) 87.3(84.6–89.6)
8.9(6.25–12.42) 13.4(10.2–17.3) 11.3(9.1–13.8)
0.9(0.22–2.42) 1.96(0.9–3.8) 1.4(0.7–2.56)
95.5(92.9–97.4) 90.5(87.0–93.2) 92.9(90.8–94.6)
4.5(2.63–7.13) 9.5(6.8–12.9) 7.1(5.35–9.20)
86.5(82.5–89.9) 80.9(76.6–84.7) 83.6(80.7–86.3)
12.3(9.0–16.13) 17.08(13.4–21.2) 14.7(12.2–17.5)
1.2(0.4–2.9) 1.96(0.9–3.8) 1.6(0.83–2.75)
Figure 1 Coverage and compliance of DEC and albendazole according to various demographic characteristics. Significant difference
(Chi square test, p<0.05) in consumption pattern was observed across different groups. Coverage in compliance according to (A)-Level of
Education; (B)-Gender; (C)-Area of residence; (D)-Different age groups.
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the operational difficulties cited by the concerned medical
officers. Both the medical officer in charge of the MDA
program and the health workers perceived that the un-
willingness of people to take the medicine was a major
hindrance in the effective implementation of this program.
People consider elephantiasis to be synonymous with
LF and mentioned that they were not observing many
lymphoedema cases in their locality. Hence, some of the
participants felt that they were not at risk of getting the
disease. One of the respondents said: “There isn’t a filar-
ial patient in our house, so it is not going to spread in
our home. Two filaria patients in our village are fromFigure 2 Reasons of non-consumption of DEC by the respondents.the same family and as they are residing at the extreme
end of the village, the infection will not attack us.”
The most common reason cited for not adhering to
DEC was the fear of side effects. One of the ladies stated:
“I would have died if I was not admitted to the head-
quarter hospital during the night after consuming the
tablets. There was no one to look after me. After the
Anganwadi worker gave me the medicine, I could not
find him again. There was no one in our nearby hospital
when I arrived there.”
Similarly another lady stated: “I was afraid of what
would happen during the night after consuming the tab-
let, so I did not consume the tablet and I did not give it
Figure 3 Major reasons for non-consumption of DEC as qouted by individuals during in depth discussions.
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someone died after consuming the tablets.”
Barriers at the distribution level
Medical officers in charge expressed difficulties in the
operationalization of the program. One medical officer
said: “The message for the purpose of MDA in the village
is not reach the people properly. This is the main cause
of non-consumption. The training should be given way
before the program commences. We did the training
quickly, so we could not do the program justice.”
Discussion and Conclusion
The present study indicated that even though the cover-
age of the MDA in Odisha was 99%, compliance was
relatively low. Mathematical models predict that an
annual mass treatment of four to six years is required
for the elimination of LF, assuming that the reproductive
life span of Wuchereria bancrofti is approximately five
years with a coverage rate of 65% [25,26].
In our study, there is difference in compliance between
males and females, as well as between the different age
groups. This difference could be due to a higher literacy
level among males as compared to the females. A de-
tailed probe into the matter might help us determine the
other cultural and social factors related to gender which
could have played a role in the compliance rate. One
reason for the increased compliance in males is that the
drugs might have been distributed in schools and stu-
dents were instructed by their teachers to consume the
tablets. No doubt, awareness and education play a cru-
cial role in the elimination of LF [17]. The present study
has identified certain aspects in which people need to be
sensitized and educated. Many respondents thought that
the disease manifested only in the form of elephantitis
and few knew that LF is vertically transmitted.The incidence of side effect estimates ranged from
25.4% to 82.1% in India [9,19], however, the majority of
the side effects were mild and infrequent [9,14]. Side ef-
fects decline with the subsequent rounds of MDA [24].
In our study, the fear of side effects was the major issue
despite good coverage. A similar result was seen in pre-
vious studies conducted in India, but the current pro-
gram has failed to solve this issue and gain faith among
individuals. An educational message describing the most
frequent, mild side effects along with simple suggestions
on how to manage them could alleviate fear and thus in-
crease MDA compliance. The educational message should
also indicate that many of the side effects are related to
the killing of LF by DEC and that the probability of side
effects decreases with the number of microfilaria also de-
creasing. A strong post distribution follow-up mechanism
might be helpful to achieve better compliance.
The second barrier to compliance identified in the
MDA program was that many people still did not
recognize the benefits of the medication. This is neither
a new nor a surprising finding [10,14]. Although the side
effects of DEC have been highly publicized, the benefits
of the drug have not been described as well. As approxi-
mately two-thirds of those infected remain asymptom-
atic, these individuals in particular may not realize that
they could personally benefit from DEC. The message
that all people living in endemic areas are at risk of in-
fection and that one could be infected even if asymp-
tomatic should be emphasized in upcoming pre-MDA
educational campaigns. Challenges from the distributor’s
perspective also need to be addressed. Operational prob-
lems such as lack of timely funding, inadequate training,
and no IEC activities need to be focused upon.
The third problem cited was the lack of availability of
health workers after drug distribution and the absence
of follow-up. The predominant reason for not receiving
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This can also be avoided. Even further, follow-up of the in-
dividuals to observe side effects and increase awareness
can be done with little extra effort. Lack of time to cover
and revisit the houses, lack of medicine for side effects
(even though they are minimal), and difficulty in receiving
the drugs from health centers were found to be hampering
the process. There is a need for an integrated approach
connecting health workers, policymakers, and the com-
munity to address the problem more comprehensively.
The inclusion of surveillance of adverse reactions after
MDA can be a proxy indicator for the consumption rate.
Issues related to the health system in procurement policy
have influenced the coverage and compliance of MDA in
Odisha. The problem at the planning level can be solved
with a proper mobilization of resources and advocacy.
We found a similar result reported by Showkat et al.
[20] and Kumar et al. [27] regarding MDA compliance.
That study was done in Kerala, the state with highest lit-
eracy rate (99%). Even though the literacy rate is higher
in Kerala, the acceptance of MDA was still low [20]. A
systematic review published in 2012 cited similar prob-
lems affecting the compliance rate globally, which de-
mands the health system to get involved and further
research to be conducted in order to address the problem
[21]. This study was cross-sectional in nature, which in-
herits the possible biases of responses. We had not probed
in detail about cultural and social barriers. Responses
obtained from children have to be considered carefully.
Policy implications
Strengthening the IEC in rural as well as in urban areas
focusing on the prevention of filariasis can be done once
a year. Sensitizating the populations about the risk and
benefits of DEC is essential. Supportive supervision and
monitoring of activities need to be strengthened and fo-
cused on in the program. Mobilization of the commu-
nity, proper training in line with the aim of the program,
and how and what type of information is given to com-
munities has to be addressed. On-the-spot administra-
tion and surveillance for adverse reactions can enhance
the compliance rates. Despite a significant reduction in
the mf rate from 2.5 to 0.4, the complete elimination of
filariasis in Odisha depends on the sustained pursuance of
MDA coverage coupled with compliance. However, this
data is for the entire state and district specific interven-
tions for the endemic areas are urgently needed. Vigorous
surveillance, advocacy, and community-based education
are also essential tools in making this goal a near reality.
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